Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant staphylococcus aureus infections

Clinical Infectious Diseases

Volumn 49, Issue 7, 2009, Pages 1072-1079

  Deresinski, Stan ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFOTAXIME; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; FUSIDIC ACID; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIUM ISOLATE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 70349934707     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605572     Document Type: Review

References (94)

1. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureusan antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543-1548
2. Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev Anti Infect Ther 2007; 5:393-401.
3. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192-197
4. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysisdependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-196
5. Lodise TP Jr, McKinnon OS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731-3733
6. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-3320
7. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vanomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199:619-624
8. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J Infect Dis 2009; 199:605-609
9. O'Neill AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidk acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47:647-650
10. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4665-4672
11. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992; 36:2709-2714
12. Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2008; 63:485-488
13. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-2440
14. Bennett JW, Murray CK, Holmes RL, et al. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2008; 60:437-440
15. Mariani PG, Sader HS, Jones RN. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006; 58:481-483
16. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104:9451-9456
17. Firsov AA, Smirnova MV, Lubenko IY, et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006; 58:1185-1192
18. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 2002; 46:1475-1480
19. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-1012
20. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50:1372-1375
21. Garazzino S, Aprato A, Baietto L, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet 2008; 47:793-805.
22. Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg 2007; 43:449-453 (Pubitemid 350085281)
23. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother 2007; 13:141-146 (Pubitemid 47012505)
24. Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008; 14:384-388
25. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-211 (Pubitemid 46080052)
26. Tuazon C, Lin MY, Sheagren JN. In vitro activity of rifampin alone and in combination with nafcillin and vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13:759-761 (Pubitemid 8323546)
27. Bahl D, Miller DA, Leviton I, et al. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:1293-1297 (Pubitemid 27231429)
28. Darouiche RO, Hamill RJ. Antibiotic penetration of and bactericidal activity within endothelial cells. Antimicrob Agents Chemother 1994; 38:1059-1064
29. Murdoch MB, Peterson LR. Antimicrobial penetration into polymorphonuclear leukocytes and alveolar macrophages. Semin Respir Infect 1991; 6:112-121
30. Ge Z, Wang Z, Wei M. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis. Eur Spine J 2008; 17:1482-1487
31. Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1985; 10:532-534 (Pubitemid 16236839)
32. Saginur R, St. Denis M, Ferris W, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50:55-61. (Pubitemid 43042902)
33. Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26:220-223
34. Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985; 151:157-165
35. Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805-819
36. Watanakunakorn C, Guerriero JC. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 1981; 19:1089-1091
37. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656-1660
38. Tsaganos T, Skiadas I, Koutoukas P, et al. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 2008; 62:381-383
39. Perdikaris G, Giamarellou H, Pefanis A, et al. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob Agents Chemother 1995; 39:2289-2294
40. Henry NK, Rouse MS, Whitesell AL, et al. Treatment of methicillinresistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82:73-75
41. Eng RHK, Smith SM, Buccini FJ, Cherubin CE. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J Antimicrob Chemother 1985; 15:201-207
42. Wichelhaus TA, Böddinghaus B, Besier S, et al. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:3381-3385
43. Levine DP, Fromm BS, Reddy R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-680
44. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2463-2467
45. Watanakunakorn C, Glotzbecker C. Enhancement of the effects of antistaphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother 1974; 6:802-806
46. Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 2000; 44:2991-2998
47. Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus awrews-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41:2497-2501
48. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49:2735-2745
49. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97:496-503.
50. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008; 62:1413-1421
51. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-665
52. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713-721
53. Bayeer AS, Murray BE. Initial low-dose aminoglycosides in Staphylococcus aureus bacteremia: good science, urban legend, or just plain toxic? Clin Infect Dis 2009; 48:722-724
54. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-e434.
55. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983; 98:447-455
56. Chu VH, Miro JM, Hoen B, et al. Coagulase-negative staphylococcal prosthetic valve endocarditis-a contemporary update based on the International Collaboration on Endocarditis: Prospective Cohort Study. Heart 2009; 95:570-576
57. Lozniewski A, Lion C, Mory F, Weber M. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and-resistant Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother 2001; 47:83-86 (Pubitemid 32058759)
58. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F. In vitro synergistic effects of double and triple combinations of β-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2000; 44:3055-3060 (Pubitemid 30803065)
59. Carricajo A, Vermesch R, Aubert G. In vitro activity of cefpirome and vancomycin in combination against gentamicin-susceptible and gentamicin-resistant Staphylococcus aureus. Clin Microbiol Infect 2001; 7: 218-220 (Pubitemid 34966121)
60. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-46661, a carbapenem newly developed in Japan. J Infect Chemother 2005;11:259-261 (Pubitemid 41570025)
61. Drago L, De Vecchi E, Nicola L, Gismondo MR. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis 2007; 7:111.
62. Chung M, Antignac A, Kim C, Tomasz A. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother 2008; 52:2709-2717
63. Fox PM, Lampen RJ, Stumpf KS, et al. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics. Antimicrob Agents Chemother 2006; 50:2951-2956
64. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179:2557-2566 (Pubitemid 27164554)
65. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999; 43: 1747-1753
66. Sieradzki K, Tomasz A. Gradual alteratons in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181:7566-7570
67. Adhikari RP, Scales GC, Kobayashi K, et al. Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus. J Antimicrob Chemother 2004; 54:360-363
68. Domenech A, Ribes S, Cabellos C, et al. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2005; 56:709-716
69. Yanagisawa C, Hanaki H, Matsui H, et al. Rapid depletion of free vancomycin in medium in the presence of ß-lactam antibiotics and growth resotoration in Staphylococcus aureus strains with β-lactaminduced vancomycin resistance. Antimicrob Agents Chemother 2009; 53:63-68
70. Ho JL, Klempner MS. In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn Microbiol Infect Dis 1986; 4:133-138
71. Booker BM, Stahl L, Smith PF. In vitro antagonism with the combination of vancomycin and clindamycin against Staphylococcus aureus. J Appl Res 2004; 4:385-395
72. Jacqueline C, Caillon J, Lc Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by timekill curve methods. J Antimicrob Chemother 2003; 51:857-864
73. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother 2003; 47:418-420
74. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:418-420 (Pubitemid 36070400)
75. Brown J, Freeman BB 3rd. Combining quinupristin/dalfopristin with other agents for resistant infections. Ann Pharmacother 2004; 38:677-685
76. Fuchs PC, Barry AL, Brown SD. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal. Antimicrob Agents Chemother 2001; 45:2662-2665
77. Pavie J, Lefort A, Zarrouk V, et al. Efficacies of quinupristin- dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to crossresistance to macrolides, lincosamides, and streptogramin B- type antibiotics. Antimicrob Agents Chemother 2002; 46:3061-3064
78. Moise-Broder PA, Forrest A, Jagodzinski LM, Paladino JA, Schentag JJ. Methicillin-resistant Staphylococcus aureus (MRSA) infections in hospitalized patients failing vancomycin (Vm): cost-effectiveness of increasing Vm versus adding quinupristin-dalfopristin (Q/D) to Vm (abstract 578). In: Program and abstracts of the 40th Annual Meeting of the Infectious Disease Society of America (Chicago). Chicago: Infectious Disease Society of America, 2002.
79. Tarasi A, Cassone M, Monaco M, et al. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. J Chemother 2003; 15:239-243
80. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22:1517-1523
81. Fujimura S, Sato T, Mikami T, et al. Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices. Int J Antimicrob Agents 2008; 32:481-484
82. Antony SJ. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 2006; 38:293-295
83. Alp E, Gozukucuk S, Canoz O, et al. Effect of granulocyte colonystimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis. BMC Infect Dis 2004; 4:43.
84. Polak J, Delia Latta P, Blackburn P. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 1993;17:265-270 (Pubitemid 24028464)
85. Walencka E, Sadowska B, Rózalska S, et al. Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin. Folia Microbiol (Praha) 2006; 51:381-386
86. Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 2007; 60:1051-1059
87. Climo MW, Patron RL, Goldstein BP, Archer GL. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 1998; 42:1355-1360
88. Cirioni O, Silvestri C, Ghiselli R, et al. Experimental study on the efficacy of combination of α-helical peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides 2006; 27:2600-2606
89. Orlando F, Ghiselli R, Cirioni O, et al. BM.P-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. Peptides 2008; 29:1118-1123
90. Rashel M, Uchiyama J, Ujihara T, et al. Efficient elimination of multidrug-resistant Staphylococcus aureushy cloned lysin derived from bacteriophage MR11. J Infect Dis 2007; 196:1237-1247
91. Domanski PJ, Patel PR, Bayer AS, et al. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 2005; 73:5229-5232 (Pubitemid 41105686)
92. NeuTec Pharma. Aurograb. Available at: http://www.neutecpharma.com/ aurograb.html. Accessed 7 February 2009.
93. del Pozo JL, Rouse MS, Mandrekar JN, et al. Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2009; 53:35-40.
94. Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious disease consultants. Clin Infect Dis 2006; 43: e42-5.